Altos Labs is a privately held American biotechnology research company founded in 2022 by Hans Bishop and Richard Klausner. Hal Barron now serves as CEO and co-chairman. The company’s mission is to restore cell health and resilience through cellular rejuvenation, with the broader goal of reversing disease, injury, and disabilities that occur throughout life.

Unlike many private biotechnology companies, Altos Labs initially focuses on basic research rather than immediate commercialization. Its work centers on cell rejuvenation, regenerative medicine, epigenetics, stem cells, and cell programming. The company aims to restore healthspan rather than simply extend lifespan.

Altos Labs stands out because of its science-first model, large-scale funding, global research hubs, and backing from major technology investors such as Jeff Bezos and Yuri Milner. Its hubs include Tokyo, San Diego, and Cambridge, giving the company access to leading scientific ecosystems and research talent.

The company’s future growth depends on building a strong research pipeline, entering preclinical and clinical trials, publishing influential scientific studies, and eventually developing commercial therapies for age-related diseases. Long-term opportunities include partnerships with pharmaceutical companies, expansion into precision medicine, and entry into the longevity and wellness markets.